Preclinical studies support the rationale for combining epigenetic and immune therapies: in a syngeneic ovarian cancer mouse model, a combination of decitabine and anti-CTLA-4 significantly reduced tumor growth and prolonged survival compared to each drug alone [68]. Here, CTLA4 is linked to ovarian cancer.